Global Markets for Stem Cells
Report Highlights
2011年，全球干细胞产品市场为38亿美元。该市场预计在2012年将达到43亿美元，到2016年将达到66亿美元，从2011年到2016年的复合年增长率（CAGR）增长11.7％。
报告范围
This report discusses the implications of stem cell research and commercial trends in the context of the current size and growth of the pharmaceutical market, both in global terms and analyzed by the most important national markets. The important technologies supporting stem cells are reviewed, and the nature and structure of the stem cell industry is discussed with profiles of the leading companies, including recent M&A activity. Five-year sales forecasts are provided for the national markets and the major therapeutic categories of products involved.
分析师证书
保罗·埃弗斯（Paul Evers）参与了20年的分析药物和医疗市场。他是先前关于干细胞市场的报告的作者，也是对主要治疗类别和药物监管环境的分析。
Report Highlights
本报告：
- 美国在再生医学中的干细胞市场预计将从2007年的1.12亿美元增加到估计到2012年底的4.231亿美元，复合年增长率（CAGR）为30.5％。
- Stem cell banking was valued at $58.9 million in 2005 and $65.9 million in 2007. This is expected to rise to $155.7 million in 2012, for a CAGR of 18.8%.
- 2006年，人类成人干细胞的基于细胞的治疗剂的价值为2140万美元。2007年，这增加到了28.1美元，2012年的复合年增长率为44.0％。
Report Highlights
-
The worldwide market for stem cell, cytokine and growth factor therapies is estimated at $12.7 billion in 2005 and, rising at an average annual growth rate (AAGR) of 10.3%, is expected to reach $20.7 billion in 2010.
-
Nearly 98% of the market is consumed by blood and immune system treatments, a figure that will shrink slightly to 95% in 2010.
-
Revenues worldwide for stem cell, cytokine and growth factor therapies for all other bodily systems are expected to rise at an AAGR of 26.4% to just over $1 billion in 2010.
-
The first off-the-shelf cell therapy approved by the FDA was for wound treatment. Recently, a bone morphogenic protein (BMP) has been approved for the acceleration of spinal fusions.
Report Highlights
-
Hematopoietic stem cell therapies are still the most widely used and generate the most revenue, as can be seen in the table below. We project this will remain the case through 2007, by which time over $1.3 billion in revenues will be generated by the purchase of products and services in support of these therapies. The average annual growth rate for these products, from 2001 to 2007 is expected to be 29.2%. These revenue projections, like all others in this report, exclude fees charged by physicians for their services and general hospital costs.
-
皮肤，骨骼和软骨主要源自间充质干细胞，肌腱，韧带和脂肪细胞（然而，皮肤的表皮层来自外胚层）。皮肤更换以治疗溃疡，烧伤和手术伤口是批准的第一个“现成”活细胞疗法。这些产物的祖细胞是新生人包皮的成纤维细胞和角质形成细胞。软骨细胞（软骨产生细胞）用于修复膝盖受伤后的关节软骨，并在此过程中进行其他应用。正在开发用于修复骨骨折的组合细胞和组织工程方法。在2001年，我们估计祖细胞疗法替代皮肤，骨骼或软骨的疗法将产生约4,300万美元的收入。如上所述，到2007年，我们预计该类别将增长10倍至4.57亿美元，即48.1％的AAGR。